Given the correlation between these oncogenic compensatory pathways that promote ERα-independent cell growth and tamoxifen/fulvestrant resistance, the targeted inhibition of miR-221/222 expression is a promising strategy to prevent the acquisition of fulvestrant resistance and even treat fulvestrant-resistant breast cancer patients. The gene discussed is ESR1; the disease is breast carcinoma.